Reações cutâneas graves em crianças: como se comportam?
Severe cutaneous adverse reactions in children: how do they behave?
Débora Mutti de Almeida Monteiro; Dina Larissa Capelasso da-Costa; Chayanne Andrade de Araujo; Maria Elisa Bertocco Andrade; Fátima Rodrigues Fernandes
Resumo
Introdução: As reações cutâneas graves a medicamentos (RCGM) compreendem um grupo de doenças caracterizadas por hipersensibilidade tardia a um ou vários tipos de fármacos. Por ser uma doença potencialmente fatal, o diagnóstico precoce, bem como o início do tratamento, são de suma importância. Objetivo: Analisar a evolução das RCGM em pacientes pediátricos acompanhados em dois hospitais da cidade de São Paulo, SP. Método: Trata-se de um estudo retrospectivo baseado na análise de prontuários de pacientes atendidos no período de 2002 a 2018 em dois hospitais da capital paulista. Resultados: Não houve diferença entre os sexos, prevaleceu a faixa etária dos adolescentes, e os medicamentos mais implicados com o desenvolvimento das lesões cutâneas foram os anticonvulsivantes, sendo os principais a carbamazepina e fenitoína, sem diferença entre eles, seguidos dos antibióticos betalactâmicos. No tratamento, todos os pacientes fizeram uso de corticoides sistêmicos e anti-histamínicos, sendo que oito pacientes também receberam imunoglobulina intravenosa e um recebeu ciclosporina. A taxa de mortalidade foi baixa e, em relação às complicações e sequelas, a autoimunidade foi a mais encontrada. Conclusão: Os casos de RCGM são eventos raros na faixa etária pediátrica, todavia de alta morbimortalidade e risco de sequelas. O diagnóstico e tratamento precoces contribuem para um melhor prognóstico, sendo de suma importância a identificação da medicação associada, bem como a retirada da mesma.
Palavras-chave
Abstract
Background: Severe cutaneous adverse reactions (SCARs) comprise a group of diseases characterized by late hypersensitivity to one or more types of drugs. Because they are potentially fatal, early diagnosis and initiation of treatment are of paramount importance. Objective: To analyze the evolution of SCARs in pediatric patients followed up in two hospitals in São Paulo, SP, Brazil. Methods: This is a retrospective study based on the analysis of medical records of patients treated between 2002 and 2018 in two hospitals in the state capital. Results: There was no difference between sexes, and the age group of adolescents prevailed. Anticonvulsants were the drugs most implicated in the development of skin lesions, especially carbamazepine and phenytoin, with no difference between them, followed by betalactam antibiotics. During treatment, all patients used systemic corticosteroids and antihistamines; eight patients also received intravenous immunoglobulin and one received cyclosporine. The mortality rate was low, and regarding complications and sequelae, autoimmunity was the most commonly found. Conclusion: Cases of SCAR are rare events in the pediatric age group, but morbidity, mortality, and risk of sequelae are high. Early diagnosis and treatment contribute to a better prognosis, and identification of the associated medication as well as its withdrawal are extremely important.
Keywords
Referências
1. Cacoub P, Musette P, Descamps V, Meyer O, Speirs C, Finzi L, et al. The DRESS Syndrome: A literature review. Am J Med. 2011;124(7):588-97.
2. Ensina LF, Fernandes FR, Malaman MF, Chavarria ML, Bernd LAG. Reações de hipersensibilidade a medicamentos. Rev bras alerg imunopatol. 2009;32(2):42-7.
3. Schnyder B. Approach to the Patient with Drug Allergy. Immunol Allergy Clin North Am. 2009;29(3):405-18.
4. Fernandes FR, Taguchi MR, Cabral JEB, Ayres SS, Pimentel D, Sá LC, et al. Toxic epidermal necrolysis in newborn period: case report. Allergol Immunopathol (Madr). 2011;39(4):240-1.
5. Hsu DY, Brieva J, Silverberg NB, Paller AS, Silverberg JI. Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. J Am Acad Dermatol. 2017;76(5):811-817.e4.
6. Halevy S. Acute Generalized Exanthematous Pustulosis. In: Shear NH, Dodiuk-Gad RP, orgs. Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions: Current and Future Trends [Internet]. Singapore: Springer; 2019 [citado 2 de janeiro de 2020]. p. 105-22. Disponível em: https://doi.org/10.1007/978-981-13-1489-6_8
7. Gomes ER, Brockow K, Kuyucu S, Saretta F, Mori F, Blanca-Lopez N, et al. Drug hypersensitivity in children: report from the pediatric task force of the EAACI Drug Allergy Interest Group. Allergy. 2016;71(2):149-61.
8. Noguera-Morel L, Hernández-Martín Á, Torrelo A. Cutaneous Drug Reactions in the Pediatric Population. Pediatr Clin. 2014;61(2):403‑26.
9. Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, et al. ALDEN, an Algorithm for Assessment of Drug Causality in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case-Control Analysis. Clin Pharmacol Ther. 2010;88(1):60-8.
10. Lewis AL, Klintworth EM, Hinton JO, Gray KM. Adolescent Medication Misuse: Results from the MUSC Inventory of Medication Experiences (MIME). Adolesc Psychiatry Hilversum Neth. 2013;3(2):184-9.
11. Man CB, Kwan P, Baum L, Yu E, Lau KM, Cheng AS, et al. Association between HLA-B* 1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007;48(5):1015-8.
12. Hsu AP, Fleisher TA, Niemela JE. Mutation analysis in primary immunodeficiency diseases: case studies. Curr Opin Allergy Clin Immunol. 2009;9(6):517-24.
13. Darjani A, Alizadeh N, Abdi H, Hosseini M, Zaresharifi S. Anticonvulsant Drugs and Severe Adverse Cutaneous Drug Reactions: A Longitudinal Observational Study. Casp J Neurol Sci. 2019;5(3):127-32.
14. Dibek Misirlioglu E, Guvenir H, Bahceci S, Haktanir Abul M, Can D, Usta Guc BE, et al. Severe Cutaneous Adverse Drug Reactions in Pediatric Patients: A Multicenter Study. J Allergy Clin Immunol Pract. 2017;5(3):757-63.
15. Brockow K, Pfützner W. Cutaneous drug hypersensitivity: developments and controversies. Curr Opin Allergy Clin Immunol. 2019;19(4):308.
16. Zimmermann S, Sekula P, Venhoff M, Motschall E, Knaus J, Schumacher M, et al. Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2017;153(6):514-22.
17. Marulli AHCGCM, Carrozzo M, Chimenti MS. High-dose Intravenous lmmunoglobulin for Severe Drug Reactions: Efficacy in Toxic Epidermal Necrolysis. Acta Derm Venereol. 2003;83:430-2.
18. Bachot N, Revuz J, Roujeau J-C. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol. 2003;139(1):33-6.
19. Marcus N, Smuel K, Almog M, Prais D, Straussberg R, Landau D, et al. Successful intravenous immunoglobulin treatment in pediatric severe DRESS syndrome. J Allergy Clin Immunol Pract. 2018;6(4):1238-42.
20. Sorrell J, Anthony L, Rademaker A, Belknap SM, Callahan S, West DP, et al. Score of toxic epidermal necrosis predicts the outcomes of pediatric epidermal necrolysis. Pediatr Dermatol. 2017;34(4):433-7.
21. Wang R, Zhong S, Tu P, Li R, Wang M. Rapid remission of StevensJohnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature. Dermatol Ther. 2019;e12832.
22. Hsu DY, Brieva J, Silverberg NB, Silverberg JI. Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. J Invest Dermatol. 2016;136(7):1387-97.
23. Clement K, Nalini N. Case Report on a Rare Adverse Drug Reaction of Cefotaxime Induced Subacute Cutaneous Lupus Erythematosus. J Young Pharm. 2019;11(1):108.
24. Lian BS, Busmanis I, Lee HY. Relapsing Course of SulfasalazineInduced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Complicated by Alopecia Universalis and Vitiligo. Ann Acad Med Singapore. 2018;47(11):492-3.
25. Lee CH, Jang SJ, Oh SR, Kim HJ, Lee MS. A Case of Fatal DRESS Syndrome Caused by Dapsone in a Patient with Behcet’s Syndrome. J Korean Rheum Assoc. 2009;16(3):253-7.
26. Roujeau J-C. Immune Mechanisms in Drug Allergy. Allergol Int. 2006;55(1):27-33.
Submetido em:
25/03/2021
Aceito em:
09/05/2021
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email